• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Systemic Lupus Erythematosus - Pipeline Review, Q4 2010 - Product Image

Systemic Lupus Erythematosus - Pipeline Review, Q4 2010

  • Published: December 2010
  • 76 pages
  • Global Markets Direct

Systemic Lupus Erythematosus - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Systemic Lupus Erythematosus Pipeline Review, Q4 2010”, provides an overview of the Systemic Lupus Erythematosus therapeutic pipeline. This report provides information on the therapeutic development for Systemic Lupus Erythematosus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus. “Systemic Lupus Erythematosus-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Systemic Lupus Erythematosus.
- A review of the Systemic Lupus Erythematosus products under development by companies and universities/research institutes based on information derived from READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Systemic Lupus Erythematosus Overview
Therapeutics Development
An Overview of Pipeline Products for Systemic Lupus Erythematosus
Systemic Lupus Erythematosus Therapeutics under Development by Companies
Systemic Lupus Erythematosus Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Systemic Lupus Erythematosus Therapeutics Development
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Biotest AG
Novo Nordisk A/S
Plexxikon Inc.
Cephalon, Inc.
Human Genome Sciences, Inc.
Pfizer Inc.
Onyx Pharmaceuticals, Inc.
Merck KGaA
Genesis Research and Development Corporation Ltd.
Hollis-Eden Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
Compugen Ltd.
Accentia Biopharmaceuticals, Inc.
Dynavax Technologies Corporation
Tolerx, Inc.
Protalex, Inc.
Neovacs SA
CREABILIS Therapeutics S.r.l.
Vaccinex, Inc.
Theraclone Sciences, Inc.
Cornerstone Therapeutics Inc.
ChemoCentryx, Inc.
Taligen Therapeutics Inc.
Anthera Pharmaceuticals‚ Inc.
SuppreMol GmbH
Advanced Cancer Therapeutics
Zenyaku Kogyo Co., Ltd.
UCB S.A.
Upstate Pharma, LLC
Ampio Pharmaceuticals, Inc.
Universities/Institutes Involved in Systemic Lupus Erythematosus Therapeutics Development
Systemic Lupus Erythematosus Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Atacicept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Benlysta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epratuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY2127399 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prestara - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituxan + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Methylprednisolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Atorvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
azathioprine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Infliximab + Azathioprine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Myfortic - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prednisolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prevenar + Pneumo23 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Systemic Lupus Erythematosus - Featured News
Dec 07, 2010: Argos Initiates Phase I Clinical Trial Of AGS-009 For Treatment Of Systemic Lupus Erythematosus
Dec 03, 2010: GSK And Human Genome Sciences Announce FDA Extension Of Benlysta PDUFA Target Date
Nov 16, 2010: Anthera Suspends Enrollment And Dosing In PEARL-SC Clinical Trial To Address Reports Of Vial Problems
Nov 16, 2010: Human Genome Sciences And GSK Announce Vote Of FDA Advisory Committee To Recommend Approval Of Benlysta For Systemic Lupus Erythematosus
Nov 15, 2010: Neovacs Receives DSMB Authorization To Proceed To Fourth Dose Level Of Ifna-Kinoid In Phase I/II Trial In Lupus
Oct 06, 2010: Myrexis To Present Oral Anti-Interferon Program At American College of Rheumatology/Association Of Rheumatology Health Professionals
Sep 27, 2010: Neovacs Receives DSMB Approval For IFNa-Kinoid In Phase I/II Study In Lupus Patients
Aug 19, 2010: HGS And GSK Receive FDA Priority Review Designation For Benlysta For Treatment Of Systemic Lupus Erythematosus
Jul 29, 2010: Anthera Initiates Phase IIb Clinical Study With A-623 In Systemic Lupus Erythematosus Patients
Jul 21, 2010: Neovacs Achieves Milestone With IFNa Kinoid Clinical Development Program For Treatment Of Lupus
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos